Type IV secretion (T4S) systems translocate DNA and protein effectors through the double membrane of Gram-negative bacteria. The paradigmatic T4S system in Agrobacterium tumefaciens is assembled from 11 VirB subunits and VirD4. Two subunits, VirB9 and VirB7, form an important stabilizing complex in the outer membrane. We describe here the NMR structure of a complex between the C-terminal domain of the VirB9 homolog TraO (TraO CT ), bound to VirB7-like TraN from plasmid pKM101. TraO CT forms a ␤-sandwich around which TraN winds. Structure-based mutations in VirB7 and VirB9 of A. tumefaciens show that the heterodimer interface is conserved. Opposite this interface, the TraO structure shows a protruding three-stranded ␤-appendage, and here, we supply evidence that the corresponding region of VirB9 of A. tumefaciens inserts in the membrane and protrudes extracellularly. This complex structure elucidates the molecular basis for the interaction between two essential components of a T4S system.
T
ype IV secretion (T4S) systems mediate the translocation of DNA and protein substrates across bacterial cell envelopes (1, 2) . One T4S system subfamily, the conjugation machines, transmit DNA substrates to bacterial recipients and are responsible for widespread dissemination of antibiotic resistance and other virulence traits among bacterial pathogens (3) . A second T4S subfamily, the effector translocators, deliver DNA or protein substrates to eukaryotic target cells to aid in establishment of infection (4) .
In Gram-negative bacteria, the T4S systems are composed of a translocation channel spanning the inner and outer membranes and an extracellular pilus (3, (5) (6) (7) . The translocation channel elaborated by the phytopathogen Agrobacterium tumefaciens is composed of an inner membrane translocase whose subunits include the VirD4, VirB4, and VirB11 ATPases, the polytopic subunit VirB6, and bitopic subunits VirB8 and VirB10. In the periplasm, the channel likely is composed of VirB2 pilin and the periplasmic domains of VirB8 and VirB9. At the outer membrane (OM), a pore must form for passage of the substrate and the pilus, but, at this time, the composition or structure of this pore is not known. Extending from the cell surface is the pilus composed of VirB2 pilin and minor components VirB5 and VirB7. VirB7, a lipoprotein, interacts with VirB9 (see below) but also can be identified in the extracellular milieu even independently of other VirB protein production (1) .
For the A. tumefaciens VirB/D4 machine and related T4S systems, the VirB9 subunit is the best candidate for assembling as an OM channel or pore (6) (7) (8) (9) . VirB9-like proteins share weak sequence similarities with pore-forming secretins associated with the types II and III secretion systems, which also export macromolecular substrates across the OMs of Gram-negative bacteria (10) . As shown for many secretins, VirB9 fractionates with the OM as a complex with a cognate lipoprotein, in this case VirB7 (11) . VirB7 interacts with and stabilizes VirB9, and formation of the VirB7-VirB9 heterodimer, in turn, stabilizes other type IV components (12) . In the A. tumefaciens VirB/D4 T4S system, a disulfide bridge is formed between the reactive Cys-24 and Cys-262 residues of VirB7 and VirB9, respectively (12) (13) (14) (15) . VirB9 proteins and secretins also form higher-order multimers, with themselves or with other T4S proteins, detectable by chemical cross-linking (15) (16) (17) . However, secretins typically are refractory to detergent solubilization from the OM and display a heat-modifiable mobility shift in SDS-polyacrylamide gels, as is also the case for OM ␤-barrel proteins, including porins and other small molecule transporters (18) . VirB9 proteins instead migrate as monomers and do not show heat-modifiable mobility in protein gels (8) . These differences may reflect a more dynamic or reversible self-association of VirB9 or suggest that VirB9-like proteins adopt a different architecture at the OM than the ring-shaped secretins.
In this study, we solved the NMR structure of a complex formed between the pKM101-encoded TraO C-terminal domain (TraO CT ) and full-length TraN, homologs, respectively, of VirB9 and VirB7. TraO CT adopts a ␤-sandwich fold, around which TraN winds. This structure defines the molecular basis of VirB9 interaction with VirB7. In a mutational analysis of the A. tumefaciens VirB7 and VirB9 subunits, we supply corroborative experimental support for the heterodimer interface identified by the TraN-TraO CT NMR structure. Interestingly, two edge strands of the TraO CT ␤-sandwich (␤4 and ␤6) together with the ␤5 strand, located opposite the TraN-binding site, form an appendage that protrudes markedly from the ␤-sandwich, and the equivalent loop in VirB9 is partially exposed on the A. tumefaciens bacterial surface.
Results and Discussion
Structure Description. We identified a soluble fragment (residues 177-294; TraO CT ) of TraO, the VirB9 homolog encoded by the pKM101 conjugation system, and purified it with a soluble version (residues 17-49) of TraN, the VirB7 homolog encoded by the same system. Details of how such fragments were identified, the complex produced, and the structure determined by NMR are provided in supporting information (SI) Figs. 6 and 7 and SI Table 1 .
TraO CT has an immunoglobin-like ␤-sandwich fold consisting of nine ␤-strands and a short stretch of 3 10 helix between the first and second strands (Fig. 1) . By using DALI (19) to compare TraO CT to known structures, the structure is most similar to the recently described Near Transporter domain of IsdH/HarA from Staphylococcus aureus (DALI Z-score 5.6) and the human interleukin 4 receptor (DALI Z-score 5.5). Immunoglobin-like folds are found in many proteins of diverse function, and thus the structural similarity does not yield any functional insight. Six strands (␤1-3, ␤7-9) form the body of the sandwich; three (␤4-6) are more loosely connected and form a distinctive ␤-appendage protruding out of the body of the sandwich. The first sheet comprises strands ␤5, ␤4, ␤8, ␤9, and ␤1; the second sheet comprises ␤2, ␤3, ␤7, and ␤6 (Fig. 1) . Because the residue numbering for the two proteins does not overlap, it should be clear that, in the following analysis, residue numbers 21-42 refer to TraN, and residue numbers 177-271 refer to TraO CT (Fig. 2) . Overall, TraN forms an extended structure that wraps around ␤1 of TraO CT and caps one of the two edges of the ␤-sandwich. In addition, TraN interacts with ␤9, ␤2, and N-terminal residues of the ␤1-␤2 linker. The interface buries 1,680 Å 2 of surface area. From N to C terminus along the TraN sequence, the first major contact with TraO CT is between carbon atoms of Pro-23, Glu-24, and Pro-25 (TraN) and Met-192 of the ␤1-␤2 linker and Val-261, Gly-263 of ␤9 (TraO) (Fig. 3A) . Asp-26 amide is H-bonded by Gln-189 in the ␤1-␤2 linker. Trp-27 packs onto a shelf comprising Gly-263 and Arg-265 of ␤9 and Val 185 of ␤1 (Fig. 3A) . shows that the N␦ protons of Asn-34 are involved in a hydrogen bond with TraO CT , because it has an unusual chemical shift of ␦ N 118 ppm and ␦ H 8.5 and 9.1 ppm and has a weaker intensity signal than the other Asn/Gln side-chain TraN amides, suggesting that it tumbles as part of the whole complex rather than exhibiting internal flexibility on a fast timescale (Fig. 2) . Unfortunately, there is no information to indicate which TraO CT atoms form H bonds with Asn-34.
The differences in the average chemical shifts (⌬␦avg) between the 1 H-15 N HSQC spectra of 15 N-labeled TraO CT alone or in a 1:1 molar ratio with unlabeled TraN were mapped onto the structure of the TraO CT /TraN complex. All of the major differences lie very close to the interface of the two proteins, which is consistent with no global conformational changes in TraO CT upon TraN binding (Fig. 4 A and B) . We also examined the 1 H-15 N HSQC spectra of 15 N-labeled TraO CT fractions that eluted from the gel filtration column as a higher-molecular-weight species. When compared with monomeric TraO CT , one extensive surface patch exhibited either large differences in chemical shifts or ablation of cross-peak intensity. This region covered strands ␤2, ␤3, ␤7, residues Lys-180, Gln-183, and Tyr-184 in and around ␤1, and the ␤6-␤7 linker, and overlaps partially with the TraN-binding site (Fig. 4B ). This partial overlap may explain how TraN prevents TraO CT oligomerization.
Conservation of the VirB7-VirB9 Interaction. Close homologs of TraO were identified by using the Basic Local Alignment Search Tool (BLAST) and were aligned by using ClustalW. The TraO/ VirB9 homologs are phylogenetically conserved, and the sequence alignment of pKM101 TraO and A. tumefaciens VirB9 C-terminal domains shows many identical or well-conserved residues. We used the sequence alignment as the basis for modeling the A. tumefaciens VirB9 CT domain using Modeller (20) and default settings (Fig. 3D) . In A. tumefaciens, the interacting VirB7/VirB9 proteins form a disulfide bridge between Cys-24 of VirB7 and Cys-262 of VirB9. These residues are highlighted in the sequence alignments and on the modeled structure (orange, Figs. 2 and 3D It was not possible to identify all of the corresponding TraN/VirB7 homologs by using BLAST or to align them by using ClustalW because the sequences are short and divergent. However, one strikingly conserved feature of the TraN/VirB7 homologs is a P[ILV]NK motif that in TraN (residues 32-35) interacts with a deep hydrophobic pocket on TraO CT (Figs. 2B  and 3C ). This motif is located 15-17 residues from the lipidated cysteine residue, a distance that might be crucial in defining the position of VirB9 with respect to the membrane.
Mutational Analysis of the VirB7-VirB9 CT Interface of A. tumefaciens.
We introduced mutations at residues predicted to form the interface in the VirB7-VirB9 heterodimer of A. tumefaciens and assayed for effects on dimerization, protein stability, and virulence of the corresponding A. tumefaciens strains. In VirB7, we mutated residues I28, F29, L31, and N32 in and around the conserved ''P[ILV]NK'' motif (Fig. 2B ) to alanine (SI Table 2 ). Strains producing the two double mutants I28A/F29A and L31A/N32A as well as the triple mutant I28A/F29A/N32D (L31 of A. tumefaciens is equivalent to V33 of TraN; Fig. 2 ) accumulated the VirB7 derivatives at WT levels, but VirB9 was undetectable, consistent with a predicted heterodimerization defect (12) . Strains producing the VirB7 mutant proteins accumulated low levels of VirB10. These strains also were defective for assembly of the disulfide bridge between Cys-24 residues of two VirB7 monomers. As expected, strains producing the VirB7 mutant proteins failed to assemble T pili, transfer oncogenic T-DNA to plants, and transfer a mobilizable IncQ plasmid to recipient A. tumefaciens cells.
In VirB9, we introduced mutations in and around the hydrophobic pocket into which L31 (V33 in TraN) inserts (SI Table 2 ). The VirB9 F203W (equivalent to residue W201 in TraO CT ) and A191M (equivalent to residue M186 in TraO CT ) mutant proteins could not be detected, consistent with a predicted heterodimerization defect, although we cannot rule out the possibility of other destabilizing effects, e.g., misfolding. These mutant proteins also did not support pilus production, virulence, or gene transfer. The V202W (equivalent to V200 in TraO CT ) mutant protein was stable and formed the VirB7 disulfide cross-link but showed defects in functional assays. This mutation might still perturb the dimer interface or formation of higher-order VirB7-VirB9 multimers. Another mutation, L198F in the ␤1-␤2 linker, also resulted in loss of detectable VirB9, pilus production, and DNA transfer. Although we cannot exclude the possibility that some of the mutations may result in protein instability, taken together, engineered mutants in A. tumefaciens VirB7 and VirB9 appear to indicate that noncovalent interactions between VirB7 and VirB9 (notably between the P[ILV]NK motif of VirB7 and the hydrophobic pocket of VirB9) are necessary to promote not only the formation of the disulfide bridge between the proteins but also to generate an active complex.
Evidence for Surface Accessibility of VirB9. One of the most intriguing features of the NMR structure of TraO CT and the modeled structure of VirB9 CT is the ␤4-␤6 region extending from the C-terminal globular domain. We tested whether this region spans the OM. Previously, we showed that dipeptide LG insertions at several positions along the length of VirB9, including insertions after N216 and N226, were permissive for VirB9 function (8) . N216 is in the ␤3-␤4 loop, and the TraO equivalent, N214, is on the surface of the protein at the furthest point of the loop; N226 (N224 in A. tumefaciens VirB9) is located at the end of ␤4 (Figs. 1B and 2) . We thus introduced a FLAG epitope after N216 and N226 as well as Cys substitution mutations at N216, N226, P227, and D228 to test for surface accessibility.
We initially observed that anti-VirB9 polyclonal antibodies reacted with native VirB9 produced in WT cells by immunofluorescence microscopy (SI Fig. 8 ). Most fluorescent foci were located at A. tumefaciens cell poles, although foci also were evident at other sites on the cell periphery, consistent with previous findings (21, 22) . These antibodies did not react with intact cells of a ⌬virB9 mutant strain, establishing the specificity of the reaction for VirB9.
Next, we assayed for surface accessibility of the FLAG epitopes. As shown in Fig. 5A , the anti-FLAG antibodies reacted with VirB9 FL epitope-tagged at residue N226 but not with material on the surfaces of intact cells producing native VirB9 or cells producing the VirB9 FL variant epitope-tagged at residue N216. Most cells had polar foci, although foci were evident elsewhere at the cell periphery similar to findings for native VirB9 (21, 22) . Upon conversion of cells to spheroplasts, both VirB9 FL variants reacted with the FLAG antibodies (Fig. 5A) . Fluorescence was more uniform than observed with whole cells, possibly because of redistribution of the VirB9 variants upon spheroplasting.
We also tested for surface accessibility of VirB9 by introducing Cys residues at positions N216, N226, P227, and D228 and then assaying for alkylation of these residues. The sulfhydryl reactive reagent 3-(N-maleimidylpropionyl) biocytin (MPB) readily crosses the OM, whereas 4-acetamido-4Ј-maleimidylstilbene-2,2Ј-disulfonic acid (AMS) only inefficiently crosses the OM because its molecular mass of 536 Da exceeds the exclusion limit for porins. Thus, pretreatment of intact cells with AMS thus should block surface-displayed Cys residues from MPB labeling (23) . As shown in Fig. 5B , most or all of native VirB9, which dimerizes via its unique C262 residue with VirB7, reacted only weakly with MPB, and labeling was unaffected by AMS pretreatment. The N216C mutant protein reacted with MPB, but labeling was unaffected by AMS pretreatment, adding to evidence that this residue resides in the periplasm. In contrast, MPB strongly labeled the N226C substitution mutant in the absence of AMS pretreatment, and labeling was significantly diminished in AMS-pretreated cells. MPB also labeled the P227C and D228C mutant proteins, albeit less strongly than N226C, and again AMS pretreatment diminished MBP labeling. Similarly, native VirB9 and the N216C mutant protein did not react with mPEGmaleimide, whose large size (5 kDa) restricts labeling exclusively to surface-accessible Cys residues (Fig. 5B) . By contrast, mPEGmaleimide reacted with the N226C and P227C mutant proteins and more weakly with the D228C mutant protein, as shown by a mobility shift of Ϸ5 kDa. As observed with MPB labeling, mPEG-maleimide labeled the N226C mutant protein most strongly and the P227C and D228C mutant proteins progressively more weakly. All of VirB9 FL variants and Cys-substitution mutants under study were fully functional insofar as the corresponding strains translocated T-DNA and the IncQ plasmid RSF1010 at WT frequencies and elaborated T pili (data not shown). Taken together, therefore, results of the immunofluorescence microscopy and scanning cysteine accessibility method studies, supplied strong evidence that residues N226 and P227 of native VirB9 are surface-displayed, indicating that the protruding ␤4-6 region identified in the NMR structure spans the A. tumefaciens OM.
Conclusion
The structure of the VirB7-interacting domain of VirB9 bound to VirB7 elucidates the molecular basis of the interaction between the two proteins. The domain itself is an independent folding unit, suggesting that full-length VirB9 is a modular protein. The interface between the TraN and TraO CT is extensive and unusual. Many interactions involving ␤-fold-containing proteins are mediated through ␤-strand addition (termed ␤-addition), whereby a ␤-strand of one interacting partner is added to the edge of a ␤-sheet in the other interacting partner (24, 25) . TraN instead wraps around its binding partner perpendicularly to the direction of the sandwich and wedges one of its residues (V33) in the gap between the two ␤-sheets. VirB9 exhibits a defined structural scaffold, and sequence homology within the VirB9 family of proteins is high, and, thus, the surface position of interacting residues is likely to be similar across the VirB9 family of proteins. This may not be the case for the VirB7 family of proteins, where sequence homology is low and no defined structure was observed. However, the structure-based functional studies presented here indicate that the VirB9/VirB7 interface is conserved.
The T4S apparatus is a macromolecular machine that actively assists protein or nucleoprotein secretion through the double membrane of Gram-negative bacteria. This process should require passage through a pore at the OM, but identification of the pore has not yet been possible. One possible candidate is the VirB9 protein that is known to fractionate from the OM and is strongly associated with VirB7, a small lipoprotein, which is found only at the OM (8, 26) . Here, we supply experimental evidence that VirB9 is surface-exposed, and we identify a minimal structure in the C-terminal domain, the ␤4-␤6 region, involved in the OM topology. Our findings support a general model that VirB9 is a component of an OM channel complex; however, further studies are needed to determine the VirB9 stoichiometry, subunit composition, and overall structure of this proposed channel.
T4S systems contribute to infectious diseases through the exchange of genetic material, including antibiotic-resistance genes, among bacterial pathogens, and by the direct secretion of macromolecules into eukaryotic cells. VirB7 and VirB9 form a keystone interaction essential for assembly of the apparatus into a functioning secretion system. The structure of the VirB7-VirB9 interaction we present here provides the basis for a rational approach to the disruption of this interaction in other bacterial systems. Small molecules targeted against this interaction may be useful drugs to combat human infectious diseases where T4S plays a crucial role.
Materials and Methods
Protein Preparation, NMR Spectroscopy, and Structure Calculations. Immunofluorescence Microscopy. A. tumefaciens cells were preinduced for 4 h for synthesis of VirB proteins in broth induction medium and then placed on a sterile microscope slide coverslip and induced for an additional 24 h. Cells were fixed by sequential additions of 0.1% polylysine (60 l) and 16% paraformaldehyde-0.5% glutaraldehyde (100 l). After fixation, cells were treated with 100 mM Tris⅐HCl, pH 7.4 (100 l), with or without lysozyme (2 mg/ml) and EDTA (100 M). Cells were incubated overnight with primary antibody (1:100 in PBS 1% BSA) specific for the FLAG epitope (M2) or VirB9 and then with the second antibody, Rhodamine red-X goat anti-mouse IgG/M (for detection of the FLAG epitope) or Alexa Fluor 488 goat anti-rabbit antibodies (for detection of VirB9). Labeled cells were visualized in a BX60 microscope (Olympus, Melville, NY) equipped with a magnification ϫ100 oil immersion phase-contrast objective by either f luorescence or differential interference contrast microscopy.
Details
Labeling with MPB. Cysteine-accessibility experiments were carried out as described (27, 28) . Briefly, 2 OD 600 of a induced A. tumefaciens strain PC1009 producing Cys-substituted VirB9 derivatives were resuspended in 500 l of buffer A [100 mM Hepes (pH 7.5)/250 mM sucrose/25 mM MgCl 2 /0.1 mM KCl). Cells were untreated or treated with AMS (Molecular Probes, Eugene, OR) (100 M final concentration) for 7 min at room temperature, then treated with MPB (Molecular Probes) (100 M final concentration) for 5 min at 25°C. Biotinylation was quenched with 20 mM ␤-mercaptoethanol.
Labeling with Monomethoxy Polyethylene Glycol (mPEG)-Maleimide.
vir-induced cultures of A. tumefaciens strain PC1009 producing Cys-substituted VirB9 derivatives were concentrated to an OD 600 ϭ 20, washed, and resuspended in 500 l of 50 mM NaHPO 4 buffer, pH 7.0. Cells were untreated or treated with AMS (100 M final concentration) for 7 min at room temperature, washed to remove the AMS, and suspended in 500 l of 50 mM NaHPO 4 buffer, pH 7.0. mPEG-maleimide (5-kDa molecular mass; Nektar Therapeutics, San Carlos, CA) (5 mM final concentration) was added, and cells were incubated for 5 min at 25°C. 2-Mercaptoethanol (20 mM final concentration) was added to quench the reaction. Cells were incubated in protein sample buffer at 65°C for 15 min, and mPEG-maleimide modification of VirB9 variants was assessed by SDS/PAGE and Western immunoblot analysis with anti-VirB9 antibodies.
Immunoprecipitation and Detection of Labeled Cys Residues. MPBlabeled cells were solubilized, and VirB9 variants were immunoprecipitated to recover VirB9 from extracts containing other MPB-labeled proteins as described (7) . After SDS/PAGE and protein transfer, nitrocellulose membranes were incubated in the presence of avidin HRP (1:10,000 dilution of 2 mg/ml stock solution; Pierce, Rockford, IL). Biotinylated proteins were detected by chemiluminescence (Amersham Pharmacia, Piscataway, NJ).
